Biologic pharmaceuticals steroids

© Janssen Pharmaceuticals, Inc. 2017. All Rights Reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States. Last Updated: December 06, 2017

Tao Fu joined Portola Pharmaceuticals in June 2015 with 18 years of experience in business development, commercial strategy and management consulting in the biopharmaceutical industry. Prior to joining Portola, he was vice president and head of mergers and acquisitions and alliance management at Bristol-Myers Squibb where he was responsible for the company’s corporate development, alliance management and venture activities. Previously, he was vice president, business development at Janssen (Johnson & Johnson) where he was responsible for over 20 business development transactions, including the execution of the . license and collaboration agreement with Bayer for Xarelto ® (rivaroxaban). Earlier in his career, he held positions at Scios Inc. (a Johnson & Johnson company), McKinsey & Company, and Becton Dickinson.

Biologic pharmaceuticals steroids

biologic pharmaceuticals steroids


biologic pharmaceuticals steroidsbiologic pharmaceuticals steroidsbiologic pharmaceuticals steroidsbiologic pharmaceuticals steroidsbiologic pharmaceuticals steroids